Ref. No.: F.02(408)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2024/ Dated :-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: edprmsc@rajasthan.gov.in

E-BID FOR THE RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS

(Two Years RC ending on 31.08.2026)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	**23.07.2024 & 6.00 PM**
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	**24.07.2024 & 11.30 AM**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in
CIN:U24232RJ2011SGC035067 E-mail : edprmsc@rajasthan.gov.in

Ref. No.: F.02(408)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2024/ Dated :-

Notice Inviting e-bids

e-bids are invited up to 6.00 PM of 23.07.2024 from NABL accredited Drugs Testing Laboratories situated in India for rate contract cum empanelment for analysis of Drugs & Medicines.

Details of NIB may be seen at the website of State Public Procurement Portal https://sppp.rajasthan.gov.in/, http://eproc.rajasthan.gov.in., http://rmsc.health.rajasthan.gov.in and may be downloaded from there.

UBN.No

Executive Director (Procurement)
RMSCL

RajKaj Ref
8280363

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

e-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS

(Rate contract for two years ending on 31.08.2026)

Bid Reference	:	F.02(408)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2024/ Dated :-
Pre- bid conference	:	**03.07.2024 at 11.30 A.M.**
Date and time for downloading bid document	:	**28.06.2024 from 06.00 PM**
Last date and time of submission of online bids	:	**23.07.2024 at 6.00 PM**
Date and time of opening of Online technical bids	:	**24.07.2024 at 11.30 AM**
Cost of the Bid Document	:	**Rs. 2360/- (Including GST@ 18%)**
RISL Processing Fees	:	**Rs. 590/- (Including GST @ 18%)**
Bid Security	:	**Rs. 20000/-**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN

E-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Rate contract for two years ending on 31.08.2026)

"CONFIDENTIALITY IS THE ESSENCE OF THIS BID"

1. **LAST DATE FOR RECEIPT OF BIDS, BID FORM FEES, BID SECURITY & RISL PROCESSING FEES**

a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Shall Be Received Till 06.00 PM on **23.07.2024** By The Rajasthan Medical Services Corporation Ltd, For The Rate contract cum Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Rate contract for two years ending on **31.08.2026**) in English language. Proposal received after the closing date and time shall not be considered.

b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid Security deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.

c) The e-Bids will be received on web-portal of e-procurement of GoR i.e. http://eproc.rajasthan.gov.in. Every Bidder will be required to pay the Bid form fee Rs. 2360/- (Including GST@ 18%) for downloaded forms from the website, Bid Security as applicable in Bid condition no. **6** and processing fee of Rs. 590/- (Including GST@ 18%) of R.I.S.L. through three separate prescribed challans (***format enclosed in Annexure- I)*** in any branch of the ***Bank of Maharashtra (M.I. Road, Jaipur)*** into Account no. ***60460019022 & IFSC Code no. MAHB0000389*** throughout the country upto or through D.D. / Bankers Cheque in favour of M.D. RMSCL (tender fees and Bid Security) and MD, RISL (tender processing fees) physically in the office of RMSCL by 6.00 PM on **23.07.2024** The bidders shall submit/upload scanned copy of all the challans in Technical Bid**.** Bids will be opened only after ensuring receipt of Bid fees along with processing fees and Bid Secrity.

In the absence of Bid fees, processing fees and Bid security the Bids shall be rejected and shall not be opened.

2. **<u>Eligibility Criteria for Empanelment :-</u>**

(1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of **drug items** and the lab shall be entitled for empanelment for the categories of items for which lab has bidded and having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.

(2) ***The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department*** **and NABL accreditation with proper scope of accreditation to undertake testing of drug items.**

(3) For drug items falling in the Non Biological category, laboratory's should have an average annual turnover of **not** less than **Rs. 50 Lakh** for past preceding three years **(**2019-20, 2020-21 & 2021-22 or 2020-21, 2021-22 & 2022-23**).**

For drug items falling in the Biological category, laboratory's should have an average annual turnover of **not** less than **Rs. 1.00 Crore** for past preceding three years **(**2019-20, 2020-21 & 2021-22 or 2020-21, 2021-22 & 2022-23**).**

Only audited accounts would be considered provisional accounts would not be considered in any case.

(4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of drugs for at least three government institutions/corporation/reputed manufacturers of drug formulations.

(5) The lab should not stand banned / debarred or blacklisted by any State **or** Central Government or its Organizations or its procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.

(i) Bid rejection

(ii) Bid Security forfeiture

(iii) Agreement rejection

(iv) Performance Security forfeiture

(v) Blacklisting

(6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with HPLCs with UV detector, HPLCs with fluorescence, HPLC with RI detector {Minimum 01 Each}.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

a. Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be analyzed tested as at Annexure-VII).

b. The bidders shall submit/upload in Technical Bid scanned copies of all the challans / DD/ BC of deposits of Bid form fees, RISL processing fee and Bid Security Money.

c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.

d. **Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.**

e. Documentary evidence of having analysed Drug and medical items for last three years with a statement in the proforma as given in Annexure III.

f. Attested copy of certificate of GST registration.

g. GST returns file of last 3 month from last date of bid submission

h. Non- Conviction Certificate by the State Licensing Authority/ competent authority.

i. Annual turnover statement for 3 year i.e. **(**2019-20, 2020-21 & 2021-22 or 2020-21, 2021-22 & 2022-23**)** certified by the practicing Chartered Accountant with UDIN No.

j. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. **(**2019-20, 2020-21 & 2021-22 or 2020-21, 2021-22 & 2022-23**)** duly audited or certified by the practicing Chartered Accountant. No provisional balance sheet or Profit and Loss account would be entertained.

k. The following information in the form given in Annexure IV (a) to IV (d).

a) The list of permanent technical qualified personnel employed in the laboratory.

b) The list of sophisticated instruments available in the laboratory.

c) Micro Biological facilities available in the laboratory.

d) List of Reference Samples along with their date of procurement and quantities.

e) In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as "Not of the Standard Quality".

l. A declaration in the proforma given in Annexure V duly signed and Notarized.

m. Details of Laboratory in Annexure – VI.

n. A copy of PAN issued by Income Tax Department.

o. Documentary evidence for the constitution of the company / concern.

p. At any time prior to opening of price bid, RMSC either at their own initiate or in response to clarification requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be uploaded on e-Proc site and will be part of the tender.

q. A bidder has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 PRICE BID:

The price bid shall also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bid is liable to be rejected for the particular item. Bidders are allowed to enter the bidder name and values only**. **The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled clarifications on prices or rebates shall not be accepted.**

5 OPENING OF TECHNICAL BID AND FINANCIAL BID EVALUATION

The technical bids would be opened on scheduled date and time on eproc website i.e. https://eproc.rajasthan.gov.in. After technical evaluation physical

inspection of the laboratories may be carried out by the designated team. Thereafter financial bids would be opened of those bidders who are found finally responsive on technical criteria. The acceptable rates for analysis will be decided and communicated accordingly.

6 BID SECURITY

The Bid Security Money Deposit shall be Rs. 20,000/- (Rs Twenty Thousand only) The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the ***Bank of Maharashtra (M.I. Road, Jaipur)*** into Account no. ***60460019022 & IFSC Code no. MAHB0000389*** throughout country or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on 23.07.2024 Bid Security Deposit in any other form will not be accepted

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails to sign the contract agreement or fails to furnish the security deposit within the stipulated time.

Government undertaking PSU are exempted from Bid Security deposition on producing the certificate issued by the competent authority.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. *The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test.* ***However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ.***
3. The rates quoted should be exclusive of taxes, though the applicable taxes are to be mentioned separately.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the rate contract period including extensions, if any given.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test to any other laboratory.
7. RMSCL shall have the right to cause inspection of the laboratory by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.

8. Conditional tender will not be accepted and rejected immediately.
9. ***GST at applicable rate should be mentioned by the bidder where evere applicable.***

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria specified in bid document.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bids depending on the volume of analytical work.

9. AGREEMENT

1. **The agreement with empanelled laboratories shall remain valid up to 31.08.2026. If Required period of contract can be extended upto 3 months on same rate, terms and condition without any prior consent of the bidder and shall be binding on approved bidder.**
2. RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value **Rs. 500 /-** (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL. (Annexure IX)
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any other person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or emailed on its email address or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

1. The successful Bidders shall be required to pay a Performance Security of **Rs. 50,000/-** (Rs Fifty Thousand only) ***in the form of demand draft*** at the time of execution of the agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:

i. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)

ii. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.

b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.

c) Mentioning only "COMPLIES" or "PASSES" in the result column of the report would be treated as incomplete report, if the result has some numerical value.

d) Every test report must have remarks either as "Standard Quality" or
for past
for past
for past
"Not of Standard Quality". Any ambiguity/cutting in reports will not be accepted (clear mention of "standard quality or not of standard quality" should be stated in bold letters and crossing/cutting of one of these will not be accepted).

e) Reports should be in A4 size (8.27" X 11.69") paper of good quality.

f) Report should be issued on form 39 A and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests,

protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.

g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.

2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / e-mail and the report should be sent along with protocol.

3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.

4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.

5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.

6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust

any further testing job to the laboratory based on facts brought out during such inspections.

7. The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.
8. It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYM ENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.
4. **GST shall be applicable as per prevailing rates notified by the Government.**

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and deposit security amount within the time specified or withdraws the BID after intimation of the acceptance of the BID or owing to any other reasons, is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money amount deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final and binding.
2. After entering into Rate contract, if the laboratory does not as per the terms and conditions, it may be disqualified to participate in the BID for the period as decided by RMSCL.

3. To assess the correctness of the test results being given by the Empanelled laboratories, samples at random, would also be sent to the Government Analyst for testing and if any variation is found the result would be informed to empanelled laboratories. If there is any gross variation in the analytical reports furnished by the empanelled laboratories (either pass or fail) with Government Lab for 3 times in assay test and 4 times for any other specification, in a year, the empanelled laboratory shall be considered for blacklisting for a period as considered proper after following the due process.

4. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.

5. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate, the empanelment of any laboratory either wholly or in part at one month's notice without assigning any reasons. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.

6. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.

7. (i)If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance it shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of ***furnishing the test report***.

   (ii)The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

(iii)**Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of ***testing charges*** which the Bidder has failed to submit:-

(a) Delay upto one fourth period of the prescribed testing period; 2.5%

(b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

(c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

iv. If, at any time during the continuance of this Agreement, the ***laboratory*** has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the ***RMSCL*** purely at his discretion for such period as may be considered reasonable. No further representation from the ***laboratory*** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

First Appellate Authority:- MD, NHM, Rajasthan, Jaipur.

Second Appellate Authority:- The Additional Chief Secretary/ Principal Secretary/ Secretary Department of Medical Health and Family Welfare, Government of Rajasthan, Jaipur.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate

Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of empanelment;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a empanelment process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a empanelment process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official

duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.+

19. APPLICABILITY OF RULES

Besides above conditions all the provisions of RTPP Act 2012 & RTPP Rules 2013 shall be applicable.

Managing Director
Rajasthan Medical Services Corporation

Annexure I

मुख्यमंत्री निःशुल्क दवा योजना

Format of Challan



Annexure - 1

Customer Copy

बैंक ऑफ महाराष्ट्र
Bank of Maharashtra

BANK OF MAHARASHTRA

DIST. NO.

Branch: M.I. ROAD BRANCH

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: 60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps.
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹ 0 0 - 0 0

Commission ₹ 0 0 - 0 0

Total amount ₹ 0 0 - 0 0

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

AUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

बैंक ऑफ महाराष्ट्र
Bank of Maharashtra

BANK OF MAHARASHTRA

DIST. NO.

Branch: M.I. ROAD BRANCH

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: 60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps.
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹ 0 0 - 0 0

Commission ₹ 0 0 - 0 0

Total amount ₹ 0 0 - 0 0

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

RajKaj Ref
8280363

ANNEXURE- II
Ref. Clause No. 2 (3), 3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover of M/s._____ for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Lacs (Rs)
1	2019-20	
2	2020-21	
3	2021-22	
Total		**Rs.** **Lacs**
Average turnover per annual		**Rs.** **Lacs**

Or

S.No.	Years	Turnover in Lacs (Rs)
1	2020-21	
2	2021-22	
3	2022-23	
Total		**Rs.** **Lacs**
Average turnover per annual		**Rs.** **Lacs**

Date:

Siganture of Auditor/
Chartered Accountant

Seal:
UDIN No.

(Name in Capital)

ANNEXURE III
Ref. Clause No: 3 (e)

PROFORMA FOR PERFORMANCE STATE MENT
(for a period of last 3 years)

Name of the Laboratory : _____

Address:_____

_____

_____

Types of Samples Analysed No. of Samples Analysed during

(2019-20, 2020-21 & 2021-22 or 2020-21, 2021-22 & 2022-23

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Specify)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :
Date :
Name of the Lab :
Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTM ENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drug items)

Signature :

Date :

Nam e of the Lab :

Office Seal :

ANNEXURE – IV (b)

Ref. Clause No: 3(j) (b)

LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS AVAILABLE IN THE LAB

S.No.	Name of the Equipment Instruments / Apparatus	Make & Description	Date of Installation	Date of last Validation	Approved for testing of drugs from State licensing Authority since….

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

LISTOF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMETN AND QUANTITIES

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O_____, Age_____, resident of_____, am proprietor /Partner/Director having our office at_____ and the approved drug testing laboratory at_____do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (Rate contract for two years ending on **31.08.2026**) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drug items for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drug items have been obtained on Form 37 bearing No._____which is valid/renewed up to_____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

   Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

That I/We have carefully read all the conditions of bid in Ref. No.**:** F.02(382)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-11/2023/ Dated :-

6. That we have testing facilities as per testing parameters mentioned in respective pharmacopoeias (IP/BP/USP etc.) and quoted for products as given below:-

Sr No.	**Quoted item Code No. (as per mention in Annexure-VII)**
1.	**For Example** 2
2.	
3.	

7. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Rate contract for two years ending on **31.08.2026**) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.
8. I/ we hereby declare under Section 7 & 11 of Rajasthan Transparency in Public Procurement Act, 2012. that:
    a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
    b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the **State Government or any local authority** as specified in the Bidding Document;
    c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
    d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
    e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
    f. I/we have complied and shall continue to comply with the Code of Integrity as specified in the Rajasthan Transparency in Public Procurement Act, the Rajasthan Transparency in Public Procurement Rules and this Bidding Document, till completion of all our obligations under the Contract.
9. Our complete address for communication with phone no.:-

---

10. E mail address :- ----------

11. Bank detail for e banking :-

    Name of account holder ……

    Full name of Bank with Branch ……

    A/c no. with full digits……..

    IFSC code ……..

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I……..S/o……(Designation)…….

Affirm on oath that the contents/information from para 1 to 11 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the Bid Security deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ANNEXURE – VI
Ref.Clause No: 3

(I)

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :

   Phone No (landline) :

   Fax :

   E-mail :

2. Other Branches & their Address (if any) :

3. Whether the firm has it own manufacturing unit? :

   If yes give details of address, license number etc.

4. Date of Inception :

5. Approval No. & Date :

6. Issued by :

7. Valid up to :

8. Schedule L-1 certificate its no. and date of issue (GLP) :

   or

9. (i) NABL Accreditation no. & date
   (ii) Scope of Accreditation
   (iii) Its validity.

10. Name of the authorized signatory :

11. Specimen Signature of the authorized Signatory :

12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

NOTE:-

- **Bidders have to mention quoted item code in annexure V for which have testing facility as per respective pharmacopoeias (IP/BP/USP etc).**

A. Non Biological Items

S. No.	Code No.	Name of item with specification
1.	81	Benzathine Benzylpenicillin Inj IP 12 lac units [81]
2.	117	Griseofulvin Tablet IP 125 mg [117]
3.	136	Chlorambucil Tab IP 5 mg [136]
4.	149	L-Asparaginase Inj 10000 IU [149]
5.	174	Heparin Sodium Injection IP 5000 IU/ml [IM/IV Use] [174]
6.	202	Methyldopa Tab IP 250mg Film Coated [202]
7.	551	Isoprenaline Injection IP 2mg / ml [551]
8.	612	Betaxolol Eye Drops 0.5 o/o IP [612]
9.	697	Ketorolac Tromethamine Dispersible Tablet 10 mg (each Uncoated Dispersable tablet Contains Ketorolac Tromethamine 10 mg) [697]
10.	702	Tab Divalproex Extended Release IP 250 mg (Each Extended Release Film Coated Tablet contains Divalproex Sodium IP Equivalent to Valproic acid 250 mg) [702]
11.	704	Tab Lacosamide 100 mg (Each Film Coated Tablet contains Lacosamide 100 mg) [704]
12.	708	Inj. Ceftriaxone 1 gm + Tazobactum 125 mg [708]
13.	709	Cefadroxil Dispersible tablet 250mg (each uncoated Dispersible tablet contain Cefadroxil equivalent to anhydrous cefadroxil 250 mg) [709]
14.	713	Tab. Faropenem Sodium 200 mg (Each Film Tablet contains Faropenem Sodium equivalent to Faropenem Sodium 200 mg) [713]
15.	722	Tab. Valganciclovir 450 mg [722]
16.	738	Mycophenolate mofetil Capsule/Tablets IP 250 mg (Each Capsule/Tablets Conatin Mycophenolate mofetil IP 250 mg) [738]
17.	740	Tab. Mycophenolate Sodium 360 mg (Each Enteric Coated tablet Conatin Mycophenolate Sodium 360 mg) [740]
18.	NE25	Moxifloxacin Tablets 400mg
19.	NRD-5	Racecadotril 100mg Cap. IP
20.	NRD-7	Acitretin 10 mg Cap. IP
21.	NRD-8	Acitretin 25 mg Cap. IP
22.	NRD-9	Alectinib 150 mg Cap.
23.	NRD-11	Anti-Oxidants (Beta Carotene-10 mg,Vit-E 25mg,Vit-C 100 mg,Copper 1.5 mg,Managanese 1.5 mg,Zinc 7.5 mg,Selenium 150 microgram) Cap.
24.	NRD-12	Aprepitant 125 / 80 mg Capsule / Tablet kit (each kit contains 1 Capsule / Tablet of 125 mg & 2 Capsule / Tablet of 80mg)
25.	NRD-14	Calcium Dobesilate 500MG Cap.
26.	NRD-18	Ceritinib Capsule 150mg
27.	NRD-19	Clomipramine IP 25 mg Capsule / Tablet IP
28.	NRD-20	Cyclosporine 100 mg Cap. IP
29.	NRD-21	Dacarbazine 200 mg Inj. USP
30.	NRD-22	Danazol 100mg Cap. IP
31.	NRD-24	Formetrol 12mcg + Budesonide 400 mcg. Powder for Inhalation
32.	NRD-25	Indacaterol and Glycopyronium inhalation powder 110/50 mcg Cap.
33.	NRD-26	Isotretinoin 10mg Cap. IP
34.	NRD-27	Isotretinoin 20 mg Cap. IP
35.	NRD-29	Minocycline 100mg. Capsule / Tablet
36.	NRD-30	Mycophenolate Mofetil 500MG Capsule / Tablet
37.	NRD-32	Ramipril IP 5 mg Capsule / Tablet IP
38.	NRD-33	Rucaparib 200 mg Cap.
39.	NRD-34	Rucaparib 300 mg Cap.
40.	NRD-35	Silodosin 4 mg Tablet / Capsule
41.	NRD-36	Silodosin 8 mg Tablet / Capsule
42.	NRD-37	Temozolamide 250 mg Cap. IP

S. No.	Code No.	Name of item with specification
43.	NRD-38	Vitamin A 25000 IU Cap. IP
44.	NRD-46	Amorolfine 0.25% Cream
45.	NRD-47	Azelaic acid 20% Cream
46.	NRD-48	Benzoyl Peroxide Gel 2.5 % IP
47.	NRD-49	Desonide 0.05% Cream
48.	NRD-51	Glycolic Acid 6% Cream
49.	NRD-52	Hydrocortisone 1% Cream IP
50.	NRD-53	Hydroquinone 2% Cream USP
51.	NRD-55	Luliconazole 1% w/w Cream IP
52.	NRD-56	Mometasone 0.1 % Cream IP
53.	NRD-58	Neomycin Sulphate 0.5% Cream
54.	NRD-60	Adaplene (0.1% W/W) Gel
55.	NRD-65	Salmetrol 50mcg+Fluticasone 500 mcg DPI IP
56.	NRD-66	Budesonide 400 mcg DPI IP
57.	NRD-70	Levosalbutamol 100mcg+ Ipratropium Bromide 40mcg DPI
58.	NRD-71	Diastase, Pepsin with simethicone 15ml Drop Each ml contains Diastase (1:1200) 33.33mg, Pepsin (1:3000) 5mg & Simethicone emulsion 40mg
59.	NRD-76	Hydroxyzine Hydrochloride Oral Solution / Drop 6mg/ml
60.	NRD-77	Ambroxol Drop 7.5mg/ml 15ML
61.	NRD-78	Anticold Drop (Each ml contains Paracetamol 125mg, Chlorpheniramine Maleate 1mg & Phenylepherine hydrochloride 2.5 mg) 15 ml
62.	NRD-81	Ferrous Ascorbate & Folic acid Drops 15ml (each ml contains Ferrous Ascorbate 10mg and Folic acid 100mcg)
63.	NRD-83	Vitamin – E 50mg/ml Drops 15ml
64.	NRD-84	Vitamin D3 400IU/ml Drop
65.	NRD-85	Vitamin D3 800IU/ml Drop
66.	NRD-87	Lactulose Enema 20%
67.	NRD-94	Natamycin Opthalmic Suspension 5% Eye Drop IP
68.	NRD-95	Olapatadine 0.1% and Ketorolac 0.4% Ophthalmic Solution
69.	NRD-98	Brinozolamide 1% w/v and Brimonidine Tartrate 0.2% w/v Ophthalmic Suspension
70.	NRD-100	Cyclopentolate 1% Eye Drop IP
71.	NRD-101	Dorzolamide 2% Eye Drop IP
72.	NRD-102	Flurometholone 0.1% Eye Drop
73.	NRD-103	Gatifloxacin 0.30% and Prednisolone Acetate 1% Ophthalmic Suspension
74.	NRD-104	HPMC 0.3% Eye Drop
75.	NRD-105	Itraconazole 1% Eye Drop
76.	NRD-107	Moxifloxacin 0.5%+Ketorolac Tromethamine 0.5% Eye Drop
77.	NRD-108	Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops
78.	NRD-109	Moxifloxacin 0.5% and Prednisolone 1% Ophthalmic Solution
79.	NRD-110	Nepafenac 0.1% Eye Drop
80.	NRD-114	Proparacaine 0.5% W/v Eye Drop USP
81.	NRD-115	Sodium Chloride 5 % Eye Drop BP
82.	NRD-117	Travapost 0.004% and Timolol 0.5% Eye Drops IP
83.	NRD-118	Tropicamide 0.8% w/v + Phenylphrine HCl 5% w/v Eye Drop
84.	NRD-119	Voriconazole 1 % w/v (Lyophilized) 30mg Eye Drop
85.	NRD-120	Azithromycin 1% Eye Ointment
86.	NRD-123	Chloramphenicol 1%, Polymyxin-B Sulphate (10000 Units) and Dexamethasone 0.1% Sodium Phosphate Eye Ointment
87.	NRD-125	Itraconazole 1% Eye Ointment
88.	NRD-126	Moxifloxacin 0.5% Eye Ointment
89.	NRD-127	Sodium Chloride 6% Eye Ointment USP
90.	NRD-128	Povidone iodine Gargle 0.5% w/v
91.	NRD-129	Gatifloxacin 0.3% Eye Drop
92.	NRD-141	Metoprolol 1mg/ml Inj.
93.	NRD-143	Docetaxel Injection 80 mg/4ml
94.	NRD-145	Sodium Chloride 3% 100ml Inj. IP

S. No.	Code No.	Name of item with specification
95.	NRD-156	Artesunate Injection 120 mg [Each Combo Pack contains Artesunate Inj 120mg Vial, Sodium Bicarbonate Inj IP 5% (2ml Amp), Sodium Chloride Inj IP 0.9%(10ml Amp)]
96.	NRD-160	Azacitidine 100mg Inj.
97.	NRD-161	Azithromycin 10 ml vial equaivelent to 500 mg Inj.
98.	NRD-169	Inj.Caffeine Cirate 20mg/ml
99.	NRD-174	Carfilzomib 60 mg Inj.
100.	NRD-175	Carmustine 100 mg Inj. IP
101.	NRD-176	Caspofungin 50 mg Inj.
102.	NRD-177	Caspofungin 70 mg Inj.
103.	NRD-178	Cefipime 1000MG + Tazobactum 125MG Inj.
104.	NRD-179	Cefoperazone 1gm+Tazobactum 125mg Inj.
105.	NRD-180	Cefoperazone 500mg Inj. IP
106.	NRD-181	Ceftazidime 1gm+Sulbactam500 mg Inj.
107.	NRD-182	Ceftazidime+ Avibactum 2gm+500mg Inj.
108.	NRD-184	Ceftriaxone IP 125 mg Inj. IP
109.	NRD-185	Ceftriaxone 1000mg + Salbactum 500mg + Disodium Edetate 37mg Inj
110.	NRD-189	Cetrorelix Acetate 0.25 mg Inj.
111.	NRD-193	Cladrabine 10 mg Inj.
112.	NRD-194	Clarithromycin 500mg Inj. BP
113.	NRD-199	Cytarabine 1000 mg Inj. IP
114.	NRD-207	Decitabine 50 mg Inj.
115.	NRD-209	Degarelix 80 mg Inj.
116.	NRD-210	Degarelix 120 mg Inj.
117.	NRD-220	Docetaxel 120 mg Inj. IP
118.	NRD-221	Doxycycline for Injection 100 mg Inj. USP
119.	NRD-228	Eribulin 0.5mg Inj.
120.	NRD-229	Eribulin 1 mg Inj.
121.	NRD-230	Ertapenem sodium 1.046 gm= Ertapenem1gm Inj.
122.	NRD-236	Fluconazole 200 mg Inj.
123.	NRD-237	Fludarabine Phosphate Injection 100mg Inj. IP
124.	NRD-238	Fludarabine Phosphate Injection 50mg Inj. IP
125.	NRD-242	Fondaparinux 2.5mg Inj. USP
126.	NRD-246	Fulvestrant 250mg Inj.
127.	NRD-249	Goserelin Acetate implant 3.6 mg Inj. BP
128.	NRD-264	Invert Sugar Injection IP 10% w/v
129.	NRD-271	Lacosamide Infusion 200mg
130.	NRD-274	Levosulpride 12.5 mg/ml Injection 2ml
131.	NRD-278	Lignocaine Hydrochloride 2% 50ml vial Inj. IP
132.	NRD-285	Mephentermine 30mg/ml Injection 10ml vial
133.	NRD-289	Methotrexate 1000 mg Inj. IP
134.	NRD-291	Methylprednisolon Acetate 40mg Inj. IP
135.	NRD-294	Midazolam 5mg/ml Injection 10 ml vial
136.	NRD-296	Mitomycin 2 mg Inj. IP
137.	NRD-297	Mitomycin 40 mg Inj. IP
138.	NRD-301	Moxifloxin 400mg/100ml Inj.
139.	NRD-303	Nabpaclitaxel / Paclitaxel Nano Particle Injection 100 mg
140.	NRD-304	Nandrolone Decanoate 100mg Inj. IP
141.	NRD-305	Nandrolone Decanoate 50 mg Inj. IP
142.	NRD-319	Octreotide-LAR (long Acting Release) 30 mg Inj.
143.	NRD-322	Ornidazole 500mg Inj. IP
144.	NRD-323	Palonosetron 0.25mg Inj.
145.	NRD-326a	Peg Asparaginase 3750 IU 5 ml Inj.
146.	NRD-330	Pemetrexed 100mg Inj. IP
147.	NRD-331	Pemetrexed 500 mg Inj. IP
148.	NRD-333	Phenylephrine Hydrochloride 10 mg/ml Inj. BP/IP
149.	NRD-335	Piperacillin 1 gm + Tazobactum 125 mg Inj. IP

S. No.	Code No.	Name of item with specification
150.	NRD-336	Piracetam 200mg Inj.
151.	NRD-338	Plerixafor 24 mg Inj.
152.	NRD-353	Risperidone prolonged released Depot/Suspension 25 mg Injection
153.	NRD-354	Risperidone prolonged released Depot/Suspension 50 mg Injection
154.	NRD-361	Ropivacaine 0.75% 20ml vial Inj. IP
155.	NRD-364	Sildenafil Injection 0.8mg
156.	NRD-371	Teicoplanin 200 mg Inj. IP
157.	NRD-372	Teicoplanin 400 mg Inj. IP
158.	NRD-379	Tigecycline for injection 50mg Inj. USP
159.	NRD-381	Tobaramycin 80mg Inj. IP
160.	NRD-383	Topotecan 2.5 mg Inj. IP
161.	NRD-384	Topotecan 4 mg Inj. IP
162.	NRD-387	Trabectedin 1 mg Inj.
163.	NRD-393	Trypan blue 0.06% w/v Injection
164.	NRD-395	Triptorelin 3.75 mg Inj.
165.	NRD-396	Triptorelin 11.25 mg Inj.
166.	NRD-400	Vinorelbine 10mg Inj. IP
167.	NRD-401	Vinorelbine 50mg Inj. IP
168.	NRD-402	Vitamin D3 (600000 IU) Inj. IP
169.	NRD-411	Clotrimazole 1%+Beclomethasone 0.025% Lotion
170.	NRD-412	Ketaconazole 2% Lotion
171.	NRD-414	Minoxidil 5% Topical Solution W/V in 60ml
172.	NRD-418	Sunscreen Lotion SPF 30 (Octinoxate 7.5%, Avobenzone 2%, Oxybenzone 3%, Octocrylene 3% and Zinc Oxide 2%) 50ml
173.	NRD-419	Clotrimazole 10Mg Lozenses
174.	NRD-425	Levosalbutamol 50mcg.+ Ipratropium 40mcg. MDI
175.	NRD-426	Levosalbutamol inhalation Solution 50mcg
176.	NRD-429	Fluticasone Propionate Nasal Spray IP 50mcg
177.	NRD-431	Neomycin sulphate and Bacitracin Zinc ointment USP 5 mg + 500 IU/gm Ointment USP
178.	NRD-439	Tacrolimus 0 .03% Ointment
179.	NRD-440	Tacrolimus 0 .1% Ointment
180.	NRD-452	Bacillus Clausii Spores Suspension 2 Billion/5ml
181.	NRD-453	Formeterol 20mcg + Budesonide 0.5mg Respitory Solution/ Suspension
182.	NRD-454	Levosalbutamol 1.25mg and Ipratropium 500mcg Respiratory Solution 2.5ml
183.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution
184.	NRD-458	Glycopyrronium Inhalation Solution 25mcg 2 ml
185.	NRD-460	Tiotropium Bromide Powder for Inhalation 18mcg
186.	NRD-463	Fosfomycin Trometamol powder 3gm
187.	NRD-465	L-Arginine 3gm and Proanthocynadine 75mg Granules
188.	NRD-467	Racecadotril 10 mg
189.	NRD-475	Cefaclor Each 5 ml contain Cefaclor 125 Mg Syp. I.P.
190.	NRD-476	Codiene Phosphate and Tripolidine Syrup (Each 5ml contains Codiene Phosphate 10mg and Tripolidine 1.25mg)
191.	NRD-477	Amlodipine oral solution 1 MG/ ML Syrup B.P.
192.	NRD-481	Calcium Phosphate 200 ml Syrup (each 10ml contain elemental Calcium 300mg elemental Phosphorus 150mg Elemental magnesium 75mg Elemental Zinc 4mg Vitamin D3 200-300IU.)
193.	NRD-486	Cefuroxime Axetil oral suspension 125mg/5ml Syrup B.P.
194.	NRD-487	Clarithromycin for oral suspension / Dry Syrup 125mg/5ml
195.	NRD-488	Cefoperazone Injection 1gm
196.	NRD-489	Cyclosporine Oral solution 100mg/ml Syrup I.P.
197.	NRD-491	Cyproheptadine HCL 2mg / 5ml Syrup I.P.
198.	NRD-492	Dextromethorphan HBr + Chlorpheniramine Syrup (each 5ml contains Dextromethorphan HBr 10mg + Chlorpheniramine 2mg)
199.	NRD-494	Drotavarine HCL 20mg / 5ml Syrup/suspension
200.	NRD-495	Each 15 ml contains: Milk of Magnesia 11.25 ml+ Liquid Paraffin 3.75 ml 170 ml Syrup

S. No.	Code No.	Name of item with specification
201.	NRD-496	Paracetamol and Ibuprofen Syrup (each 5ml Contains Paracetamol 162.5mg + Ibuprofen 100 mg) 60ml
202.	NRD-497	Enzyme Syrup (Each 5ml contains Diastase 50mg & Pepsin 10mg) 100ml
203.	NRD-501	L-Carnitine 500mg/5ml in 30 ml Syrup USP
204.	NRD-503	Levofloxacin Oral Solution/ Syrup 125mg /5ml
205.	NRD-504	Linezolid 100mg/5ml in 30ml Syrup
206.	NRD-505	Mefenamice Acid 100mg/5ml Syrup
207.	NRD-508	Montelukast+Levocetrizine Syrup/suspension each 5ml contains Montelukast 4mg +Levocetrizine 2.5 mg
208.	NRD-509	Nitrofurantoin oral suspension 25mg/5ml in 100 Syrup B.P.
209.	NRD-510	Ondansetron oral suspension/solution/ Syrup 2mg/5ml
210.	NRD-512	Phenobarbitone 20mg/5ml in 100ml Syrup
211.	NRD-514	Piracetam 500mg/5ml Suspension/Syrup
212.	NRD-515	Potassium Magnesium citrate Syrup/ solution each 5ml contians Potassium citrate 1100mg + Magnesium citrate 375 mg
213.	NRD-516	Ranitidine 75 mg /5ml oral suspension/Solution /Syrup I.P.
214.	NRD-519	Sodium Picosulphate oral Suspension/ Solution/ Syrup 5mg/5ml
215.	NRD-520	Sorbitol & Tricholine Citrate Syrup / Solution Each 10ml contains Sorbitol (70%) 7.15gm & Tricholine Citrate (66%) 0.55gm
216.	NRD-521	Sucralfate Syrup/ Suspension Each 5ml contains Sucralfate 500mg Each 5ml contains Sucralphate 500mg
217.	NRD-522	Triclofos oral suspension500 mg/ 5ml in 30ml Syrup I.P.
218.	NRD-524	Zinc Oral Syrup / Solution / Suspension 20 mg / 5ml
219.	NRD-525	Azithromycin 100mg/5ml oral Syrup /Suspension
220.	NRD-526	Azithromycin 200mg/5ml oral Syrup /Suspension
221.	NRD-527	Midodrine 5mg Tab.
222.	NRD-528	Hydroxyurea 500mg Tab./Cap. I.P.
223.	NRD-530	Everolimus 5mg Tab./Cap.
224.	NRD-531	Everolimus 10mg Tab./Cap.
225.	NRD-532	Tacrolimus 0.25 Tab./Cap. I.P.
226.	NRD-533	Nintedanib 150MG Tab./Cap.
227.	NRD-535	Acebrophylline SR 200 Mg Tab.
228.	NRD-536	Aceclofenac 100mg & Thiocolchicoside 4mg Tab.
229.	NRD-537	Aceclofenac SR 200 mg Tab.
230.	NRD-538	Aceclofenac+Paracetamol+ Serratiopeptidase (100+325+15 mg) Tab.
231.	NRD-539	Afatinib 20 mg Tab.
232.	NRD-540	Afatinib 30 mg Tab.
233.	NRD-541	Afatinib 40 mg Tab.
234.	NRD-542	Alendronate Sodium 70 mg Tab. I.P.
235.	NRD-543	Alfuzosin 10 mg Tab. I.P.
236.	NRD-544	Alpelisib 150 mg Tab.
237.	NRD-546	Alpelisib 250 mg Tab.
238.	NRD-547	Amantadine 100mg Tablet / Capsule
239.	NRD-548	Amisulpride 50 mg Tab. I.P.
240.	NRD-549	Apixaban 2.5 mg Tab.
241.	NRD-550	Apixaban 5mg Tab.
242.	NRD-551	Aripiprazole 10 mg Tab. I.P.
243.	NRD-552	Aripiprazole 5 mg Tab. I.P.
244.	NRD-555	Atomoxetin 10 mg Tab.
245.	NRD-556	Atomoxetin 18 mg Tab.
246.	NRD-557	Atomoxetin 25 mg Tab.
247.	NRD-559	Axitinib 5 Mg Tab.
248.	NRD-560	Bilastin 20 MG Tab.
249.	NRD-562	Bosentan 62.5 mg Tab. I.P.
250.	NRD-565	Buprinorphine Tablet 2mg
251.	NRD-566	Calcium Acetate 667 Tab. USP
252.	NRD-568	Capmatinib 200 mg Tab.
253.	NRD-569	Carbimazole 10 mg Tab. I.P.

S. No.	Code No.	Name of item with specification
254.	NRD-570	Cefixime + Potassium Clavulanate 200+125mg Tab.
255.	NRD-571	Cefpodoxime proxetil Tablet 100mg / Cefpodoxime proxetil DispersibleTablet 100mg
256.	NRD-572	Cefpodoxime 200mg Tab. I.P.
257.	NRD-573	Cefpodoxime CV 325 Tab
258.	NRD-574	Chlordiazepoxide 25 mg Tab. I.P.
259.	NRD-575	Chlordiazepoxide 5 mg & Clidinium 2.5 mg Tablet
260.	NRD-576	Chlorthalidone 6.25 mg Tab. I.P.
261.	NRD-577	Cholchicine 0.5mg Tab. I.P.
262.	NRD-578	Cilostazol 50mg Tab. I.P.
263.	NRD-579	Cilostazol 100mg Tab. I.P.
264.	NRD-580	Clarithromycin 250 MG Tab. I.P.
265.	NRD-581	Clarithromycin 500mg Tab. I.P.
266.	NRD-582	Cilnidipine 5 mg Tab. I.P.
267.	NRD-583	Cilnidipine10 mg Tab. I.P.
268.	NRD-584	Cilnidipine 20 mg Tab. I.P.
269.	NRD-585	Clonazepam 0.25 Tab. I.P.
270.	NRD-586	Clonazepam 1Mg Tab. I.P.
271.	NRD-587	Clozapine 25 mg Tab. I.P.
272.	NRD-588	Clozapine 50 mg Tab. I.P.
273.	NRD-589	Clozapine 100 mg Tab. I.P.
274.	NRD-590	Co-trimoxazole Tablet IP 480mg (Trimethoprim 80mg+Sulphamethoxazole 400mg)
275.	NRD-591	Cefuroxime Axetil 500 mg. Tab. I.P.
276.	NRD-592	Cyproheptadine 4Mg Tab. I.P.
277.	NRD-593	Cyproterone Acetate 2 mg +Ethynil Estradiol. 035mg Tab BP
278.	NRD-594	Dabigatran 150 mg Tab.
279.	NRD-595	Dabigatran 110 mg Tab.
280.	NRD-596	Dabrafenib Capsule / Tablet 50 mg
281.	NRD-597	Dacomitinib 15 mg Tab.
282.	NRD-599	Dapagliflozin 10 MG Tab.
283.	NRD-600	Dapoxetine 30 mg Tab. I.P.
284.	NRD-602	Deflazacort 6mg Tab.
285.	NRD-603	Deflazacort 12 MG Tab.
286.	NRD-604	Desvenlafaxine 50mg CR/PR/SR/ER Tablet
287.	NRD-605	Diclofenac sodium 50mg+Paracetamol 325mg+Serratiopeptidase 10mg Tablet
288.	NRD-611	Disulfiram Tablet 500mg
289.	NRD-612	Disulfiram 250mg Tab. I.P.
290.	NRD-613	Donepezil 5 mg Tab. I.P.
291.	NRD-614	Duloxetine gastro resistant 20 mg Tab. I.P.
292.	NRD-615	Duloxitine gastro resistant30 mg Tab. I.P.
293.	NRD-616	Dydrogesterone 10mg Tab. I.P.
294.	NRD-617	Eltrombopag 25MG Tablet / Capsule
295.	NRD-618	Eltrombopag 50MG Tablet / Capsule
296.	NRD-622	Erlotinib 150 mg Tab. I.P.
297.	NRD-623	Erlotinib 100mg Tab. I.P.
298.	NRD-624	Esomeprazole 40 Mg Tab. I.P.
299.	NRD-625	Estradiol Valerate 2 mg Tab.
300.	NRD-627	Enzalupamide 40mg Tablet / Capusle
301.	NRD-628	Ethynil Estradiol 0.02mg and Desogestral 0.15mg Tablets
302.	NRD-629	Etizolam 0.5 mg Tab. I.P.
303.	NRD-630	Etoricoxib+thiocolchicoside(60+8 mg) Tab.
304.	NRD-632	Febuxostat 40 mg Tab.
305.	NRD-633	Febuxostat 80 mg Tab.
306.	NRD-634	Fexofenadine 120 MG Tab. I.P.
307.	NRD-635	Fexofenadine 180 MG Tab. I.P
308.	NRD-638	Flunarizine 10mg Tab.
309.	NRD-639	Fluvoxamine 100 mg Tab. I.P.

S. No.	Code No.	Name of item with specification
310.	NRD-640	Fluvoxamine 50 mg Tab. I.P.
311.	NRD-643	Furosemide 20mg + Spironolactone 50mg Tab.
312.	NRD-645	Ibrutinib 140mg Tablet / Capsule
313.	NRD-646	Indomethacin 75 mg SR Tablet / Capsule
314.	NRD-648	Ivabradine 5mg Tab.
315.	NRD-649	Ivermectin 6 mg + Albendazole 400 mg Tab.
316.	NRD-650	Ivermectin 6mg Tab. I.P.
317.	NRD-651	Ivermectin 12mg Tab. I.P.
318.	NRD-652	Ketoconazole 200 MG Tab. I.P.
319.	NRD-653	Lacosamide 50 mg Tab. B.P.
320.	NRD-654	Lamotrigine Dispersible 100MG Tab. I.P.
321.	NRD-655	Lapatinib Tablet 250mg
322.	NRD-656	Lenalidomide 25MG Tab.
323.	NRD-657	Lenalidomide 10 mg Tab.
324.	NRD-658	Lenvatinib 4 mg Tab.
325.	NRD-659	Lenvatinib 10 mg Tab.
326.	NRD-660	Levetiracetam IP 250 mg Tab. I.P.
327.	NRD-662	Levodopa+Carbidopa+Entacapone 100mg/25mg/200mg Tab.
328.	NRD-663	Levofloxacin 750 mg Tab. I.P.
329.	NRD-665	Tab. Thyroxine / Levothyroxine Sodium 25 mcg I.P.
330.	NRD-666	Tab. Thyroxine / Levothyroxine Sodium 75 mcg I.P.
331.	NRD-668	Linaglipitin 5mg Tab.
332.	NRD-669	Lopinavir 200Mg+Ritonavir 50 mg Tab. I.P.
333.	NRD-670	Loratadine 10 mg Tab. I.P.
334.	NRD-673	Megestrol Acetate 160 mg Tab. I.P.
335.	NRD-674	Melatonin 3 mg Tab.
336.	NRD-675	Melphalan 2mg Tab. I.P.
337.	NRD-678	Methimazole 10mg Tab. USP
338.	NRD-682	Methylprednisolone 4mg Tab. I.P.
339.	NRD-683	Methylprednisolone 16mg Tab. I.P.
340.	NRD-684	Methylprednisolone 8mg Tab. I.P.
341.	NRD-689	Mirtazapine 7.5mg Tab. I.P.
342.	NRD-690	Mirtazapine 15mg Tab. I.P.
343.	NRD-692	Montelukast 4 mg Tab. I.P.
344.	NRD-693	Montelukast 5 mg Tab. I.P.
345.	NRD-694	Montelukast 10 mg Tab. I.P.
346.	NRD-695	Morphine 10MG Tab. I.P.
347.	NRD-697	Moxifloxacin 400 Mg Tab. B.P.
348.	NRD-698	Moxonidine 0.2 mg Tab. B.P.
349.	NRD-699	Moxonidine 0.3 mg Tab. B.P.
350.	NRD-700	N-Acetylecystine effervescent form, orange flavour, 600 mg Tab.
351.	NRD-701	Naltrexone 50 mg Tab. I.P.
352.	NRD-702	Nebivolol 5mg Tab. I.P.
353.	NRD-703	Nebivolol 10mg Tab. I.P.
354.	NRD-704	Nicorandil 5mg Tab. I.P.
355.	NRD-705	Nicoumalone 1 Mg Tab. I.P.
356.	NRD-706	Nicoumalone 3 Mg Tab. I.P.
357.	NRD-707	Nicoumalone 4 Mg Tab. I.P.
358.	NRD-708	Nifidipine Capsule 10mg
359.	NRD-709	Nifidipine 20MG SR Tab. I.P.
360.	NRD-710	Nilotinib 150 mg Tablet / Capsule
361.	NRD-711	Nilotinib 200 mg Tablet / Capsule
362.	NRD-713	Nitazoxanide 500mg Tab.
363.	NRD-714	Nitrazepam 5mg Tab. I.P.
364.	NRD-715	Nitrazepam 10 mg Tab. I.P.
365.	NRD-716	Olaparib 100 mg Tablet
366.	NRD-717	Olaparib 150 mg Tablet
367.	NRD-718	Olmesartan medoxomil 20 MG Tab. I.P.

S. No.	Code No.	Name of item with specification
368.	NRD-720	Osimertinib 80 mg Tablet
369.	NRD-721	Oxcarbazepine 300MG Tab. I.P.
370.	NRD-722	Oxcarbazepine 450MG Tab. I.P.
371.	NRD-723	Oxazepam 15mg Tab. I.P.
372.	NRD-725	Pantoprazole 20MG Tab. I.P.
373.	NRD-726	Paracetomol 650 mg Tab. I.P.
374.	NRD-727	Paroxetine 12.5 mg Control Release / Prolonged Release Tablet
375.	NRD-728	Paroxetine 25 mg Control Release / Prolonged Release Tablet
376.	NRD-729	Pazopanib 200mg Tablet / Capsule
377.	NRD-730	Pazopanib 400mg Tablet / Capsule
378.	NRD-735	Pheniramine 25 MG Tab. I.P.
379.	NRD-737	Pirfenidone 200 mg Tab. I.P.
380.	NRD-738	Pirfenidone 400 mg Tab. I.P.
381.	NRD-739	Piroxicam DT 20mg Tab. I.P.
382.	NRD-740	Pomalidomide 2 mg Tab.
383.	NRD-741	Pomalidomide 4 mg Tab.
384.	NRD-742	Posaconazole 100mg Tab.
385.	NRD-743	Posaconazole 40mg/ml Syp.
386.	NRD-744	Prasugrel 10MG TAB Tab.
387.	NRD-745	Prazosin 5MG Tab. ER/PR/CR
388.	NRD-746	Prednisolone IP 40mg Tab. I.P.
389.	NRD-750	Desogestrel 0.075mg Tablet
390.	NRD-751	Propranolol 10mg Tablet / Capsule
391.	NRD-752	Propranolol 40 mg SR Tablet / Capsule
392.	NRD-755	Ranolazine 500MG Tab. ER/PR/CR
393.	NRD-756	Rasagiline1MG Tab.
394.	NRD-757	Regorafenib 40 mg Tab.
395.	NRD-759	Repaglinide 1mg Tab.
396.	NRD-760	Ribociclib 200 mg Tab.
397.	NRD-764	Rifaximin 200 Tab. B.P.
398.	NRD-765	Rifaximin 550mg Tab. B.P.
399.	NRD-766	Rivaroxaban 10mg Tab. B.P.
400.	NRD-767	Rivaroxaban 15mg Tab. B.P.
401.	NRD-768	Rivaroxaban 20mg Tab. B.P.
402.	NRD-769	Rizatriptan 10mg Tab. I.P.
403.	NRD-770	Ropinirole 0.25mg Tab. I.P.
404.	NRD-771	Rosuvastatin 10mg + Fenofibrate 160mg Tab. I.P.
405.	NRD-772	Ruxolitinib 5 mg Tablet / Capsule
406.	NRD-774	Ruxolitinib 15 mg Tablet / Capsule
407.	NRD-775	Ruxolitinib 20 mg Tablet / Capsule.
408.	NRD-776	Selegiline 5mg Tab. I.P.
409.	NRD-777	Serratiopeptidase 10mg Tab. I.P.
410.	NRD-778	Serratiopeptidase 20 mg Tab. I.P.
411.	NRD-779	Sevelamer Carbonate 800 mg Tab.
412.	NRD-780	Sildosin 8 mg + Dutasteride 0.5 mg Tablet / Capsule
413.	NRD-782	Sitagliptine+Metformin (50/500) Tab
414.	NRD-783	Sildenafil 20 mg Tab. I.P.
415.	NRD-784	Sofosbuvir 400 mg+ Velpatasvir 100 mg Tab.
416.	NRD-785	Solifenacin succinate 10 mg Tab. I.P.
417.	NRD-786	Sorafenib 200 mg Tab. I.P.
418.	NRD-788	Sunitinib 12.5 mg Tab.
419.	NRD-789	Sunitinib 25 mg Tab.
420.	NRD-790	Sunitinib 50 mg Tab.
421.	NRD-791	Tacrolimus 1MG Tablet / Capsule
422.	NRD-793	Tapentadol 50mg Tab.
423.	NRD-794	Tegafur 100mg and Uracil 224mg Capsule
424.	NRD-795	Tenofovir 300MG Tab.
425.	NRD-796	Tetrabenazine 25mg Tab.

S. No.	Code No.	Name of item with specification
426.	NRD-797	Ticagrelor 90mg Tablet / Capsule
427.	NRD-798	Tofacitinib 5 mg Tab.
428.	NRD-799	Tolvapatan 15mg Tab.
429.	NRD-800	Topiramate 50MG Tab. I.P.
430.	NRD-801	Torsemide 20mg Tab. I.P.
431.	NRD-802	Tramadol 37.5mg + Paracetamol 325mg Tab.
432.	NRD-804	Trimetazidine HCl Modified Release Tablet 35mg
433.	NRD-805	Trimetazidine Hydrochloride Modified Release (CR/SR/PR) 60 mg Capsule/Tablet
434.	NRD-806	Trypsin 48mg + Rutoside 100mg + Bromelain 90 mg Tablet
435.	NRD-807	Trypsin Chymotripsin Tablet (Each enteric coated tablet contains 1 Lacks unit of enzymetic activity)
436.	NRD-808	Ulipristal 5mg Tab.
437.	NRD-809	Voriconazole 200 mg Tab. I.P.
438.	NRD-812	Vildagliptin 50mg Tab. I.P.
439.	NRD-813	Voglibose 0.2 mg Tab Tab. I.P.
440.	NRD-814	Voglibose 0.3 mg Tab Tab. I.P.
441.	NRD-815	Warfarin 1MG Tab. I.P.
442.	NRD-816	Warfarin 2MG Tab. I.P.
443.	NRD-817	Warfarin 3MG Tab. I.P.
444.	NRD-818	Zinc 50MG Tab.
445.	NRD-819	Zolpidem 10mg Tab. I.P.
446.	NRD-820	Zonisamide 50mg Tab.
447.	NRD-821	Zonisamide 100 mg Tab.
448.	NRD-822	Tiotropium Inhalation 9mcg

B. Biological Items

S. No.	Code No.	Name of item with specification
449.	171	Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 250 IU/ Vial (IV use)
450.	175	Human Albumin Solution IP 20%
451.	176	rh-Erythropoetin Inj IP 10000 IU
452.	177	rh-Erythropoetin Inj IP 2000IU
453.	179	rh-Erythropoetin Inj IP 4000 IU
454.	209	Streptokinase Injection 15 lac units IP
455.	225	Anti A Blood Grouping Serum IP(Anti A Monoclonal Serum)
456.	226	Anti B Blood Grouping Serum IP(Anti B Mono Clonal Serum)
457.	227	Anti D(Rh) Blood Grouping Serum IP/Anti D Blood Grouping Serum IP
458.	242	VDRL Antigen (with + ve and - ve control) / RPR Slide Kit
459.	279	Biphasic Isophane Insulin Inj IP (30 % soluble insulin and 70 % isophane insulin) inj. 40 IU/ml(R-DNA Origin)
460.	294	Isophane Insulin Inj IP 40 IU /ml
461.	300	Insulin Injection IP (Soluble Insulin/Neutral Insulin Injection)40 IU/ml(r.DNA origin)
462.	303	Human Anti D Immunoglobulin Injection IP 300mcg (IM use)
463.	304	Human Anti D Immunoglobulin IP 150 mcg / Human Anti D Immunoglobulin 150 mcg
464.	305	Human Rabies Immunoglobulin Inj IP 150 IU/ ml
465.	306	Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU
466.	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose
467.	308	Snake Venum Anti Serum IP (Lyophilized)Polyvalent Anti Snake Venum,Serum Enzyme Refined.Contain purified equine globulins.1 ml of serum neutralizes 0.6 mg of cobra venum,0.45 mg of common kraite(Bungaras)venum(Details in RC)
468.	309	Tetanus Immunoglobulin IP 250 IU/ Vial
469.	310	Tetanus Vaccine (adsorbed) IP 5 ml vial

S. No.	Code No.	Name of item with specification
470.	406	Factor IX Concentrate (Purified) IP 500-600 I.U.(Human Coagulation Factor IX)
471.	407	Anti Inhibitor Coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 I.U. per Vial)
472.	408	Rabies Antiserum IP (Equine) 300 units per ml contains equine anti-rabies immunoglobulin fragments (I.M./SC use)
473.	480	Diphtheria Antitoxin IP 10000 IU
474.	525	Alpha Interferon Injection Interferon Alpha 2 concentrated Solution IP 3 Million Unit
475.	530	Filgrastim Injection IP (Granulocyte Colony Stimulating Factor) (SC/IV use) 300 mcg
476.	557	Urokinase Injection 5 Lac Unit (Lyophilized)
477.	633	Normal Human Intravenous immunoglobulin IP5g/100ml
478.	635	Surfactant for intratrecheal instillation (natural bovine lung surfactant)
479.	680	Insulin Glargine 3ml IP (100IU/ml) with 15 Insulin Syringes and needles/Cartridge 3ml (100IU/ml) with 15 needles and 1 pen per 20 cartridges
480.	688	Dried Factor VIII Fraction IP (IV use) 500 IU/Vial
481.	689	Dried Factor VIII Fraction IP (IV use) 1000 IU/Vial
482.	690	Recombinant Coagulation Factor VIIa 1mg
483.	691	Recombinant Coagulation Factor VIIa 2mg
484.	693	Insulin Glargine IP 10 ml vial (100 IU/ml) with 30 Insuline syringes with Needle
485.	734	Bevacizumab Injection 400 mg
486.	735	Bevacizumab Injection 100 mg
487.	748	Recombinant F IX 500 IU with diluent
488.	749	3rd Generation Recombinant F VIII 250 IU with diluent
489.	750	3rd Generation Recombinant F VIII 1000 IU with diluent
490.	767	Hepatitis B Immunologlobin Injection IP 200 I.U
491.	774	Human Chorionic Gonadotropin Injection IP 5000 I.U.
492.	796	Inj Poractant Alpha 80 mg/ml in pack of 1.5 ml (Detail in RC)
493.	798	Human Immunoglobulin Inj with 12%IgM,12%IgA,76%IgG in pack of 10ml(0.5gm)
494.	NRD-147	Adalimumab 40 mg Inj.
495.	NRD-151	Prostaglandin 500MCG/ml Inj. 1 ml vial
496.	NRD-158	Avelumab 200 mg Inj.
497.	NRD-164	Botulinum Toxin Type A for injection 100 IU
498.	NRD-165	Botulinum Toxin Type A for injection 50 IU
499.	NRD-190	Cetuximab 100 mg Inj.
500.	NRD-191	Cetuximab 500mg Inj.
501.	NRD-202	Daratumumab 100 mg Inj.
502.	NRD-203	Daratumumab400 mg Inj.
503.	NRD-204	Darbepoietin Alfa 100mcg Inj.
504.	NRD-205	Darbepoietin Alfa 200 mcg Inj.
505.	NRD-206	Darbepoietin Alfa 500mcg Inj.
506.	NRD-211	Degludec insulin 100IU/ml Injection 3ml
507.	NRD-212	Denosumab 120 mg Inj.
508.	NRD-214	Detemir Insuline 100IU/ml Injection 3ml
509.	NRD-222	Durvalumab 120 mg Inj.
510.	NRD-223	Durvalumab 500mg Inj.
511.	NRD-244	FSH 75 IU Inj.

S. No.	Code No.	Name of item with specification
512.	NRD-252	Horse ATG(Anti Thymocyte Globulin) 250 mg Inj.
513.	NRD-253	HP HMG (Highly Human Menopausal parodied Gonadotropin) 150 IU Inj. IP
514.	NRD-257	Inotuzumab Ozogamicin Injection 1mg
515.	NRD-258	Insulin Aspart IP 100IU/ml Injection 3 ml
516.	NRD-260	Insulin Glulisine (Monocomponent Insulin Glulisine) 100 IU/ml Injection 3 ml
517.	NRD-261	Insulin Lispro IP Injection
518.	NRD-262	Interferon Beta 1 a Injection IP 30mcg
519.	NRD-306	Natalizumab 300 mg Inj.
520.	NRD-312	Nimotuzumab 50 mg Inj.
521.	NRD-321	Omalizumab 150 mg vial Inj.
522.	NRD-326b	Peg Asparaginase 3750 IU 5 ml Inj.
523.	NRD-327	PEG filgrastim injection 6mg Inj.
524.	NRD-332	Pertuzumab injection 600 mg and Transtuzumab 600 mg in 10 ml
525.	NRD-346	Ranibizumab Injection (10mg/ml) 2.3mg/0.23ml per vial
526.	NRD-347	Rasburicase 1.5 mg Inj.
527.	NRD-348	Recombinant FSH 150 IU Inj.
528.	NRD-349	Recombinant FSH 300IU Inj.
529.	NRD-351	Recombinant LH 75IU Inj.
530.	NRD-352	Reteplase 18 mg Inj.
531.	NRD-355	Rituximab 100 mg Inj. IP
532.	NRD-356	Rituximab 500 mg Inj. IP
533.	NRD-359	Romiplostim 250 mcg Inj.
534.	NRD-360	Romiplostim 500 mcg Inj.
535.	NRD-363	Secukinumab 150 mg Inj.
536.	NRD-373	Tenecteplase 20mg Inj.
537.	NRD-374	Tenecteplase 40 mg Inj.
538.	NRD-385	t PA 20mg Alteplase for Injection
539.	NRD-386	t PA 50mg Alteplase for Injection
540.	NRD-389	Trastuzumab 440 mg Inj.
541.	NRD-390	Trastuzumab150Mg Inj.
542.	NRD-403	Insulin Glargine 300 IU IP per ml Inj. IP 1 prefilled pen of 1.5ml
543.	NRD-490	Rabbit ATG (Anti Thymocyte Globulin) 25mg / 5ml Inj.
544.	NRD-823	Human Albumin 20% in 50 ml Vial Inj. IP
545.	NRD-824	Tetanus Vaccine (Adsorbed) IP in 0.5 ml Inj.
546.	NRD-889	Glycopegylated Extended Half Life Nonacog Beta Pegol F Ix 500IU
547.	NRD-890	Glycopegylated Extended Half Life Nonacog Beta Pegol F Ix 1000IU
548.	NRD-891	Glycopegylated Extended Half Life Factor VIII 500IU
549.	NRD-892	Glycopegylated Extended Half Life Factor VIII 1000IU
550.	NE-79	Crizanlizumab 10mg/ml Inj 10ml

ANNEXURE –VIII
Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of insects and rodents besides cross contaminations ;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks, and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is provided & also unities like water, power and gas ;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes, thermometers etc. shall be thoroughly checked for accuracy for calibration before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be carried out in a fume cupboard	

_Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a label.	
2	A standardization register shall be maintained, with its raw date and SOP for preparation and standardization on stock solutions, standard solutions and volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner considering the physicochemical properties substances and the hazard involved in their use.	
5	General and specific written down instructions for safety shall be circulated to each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves and face masks and eye protection wherever required	
9	The laboratories shall have adequate firs aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions - 1- water showered 2- Rubber suction bulbs must be used on manual and siphons ; 3- Warnings, precautions and written Instructions violent, uncontrollable or reactions. 4- Appropriate facilities for the collection, storage and disposal of wasters. 5- Safe disposal of corrosive or dangerous products by neutralization or deactivation. 6- Safety precautions to be adopted while handling potassium cyanide and bromide ; 7- SOP for handing, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

S.N.	Details of the requirement	Remark
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	
3	Reference material shall be traceable to agency authorized by Government of India or any other International body.	

S.N.	Details of the requirement	Remark
4	The laboratory shall prepare working standard by comparing with the reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following details are to be written - a- Source of supply ; b- Code number of the reference material ; c- Date of receipt ; d- Batch number or identification number of the supplying agency ; e- Details like assay value, water content or information provided ; f- Storage condition of the material ; g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia requirements and the method demonstrably based on validation protocols are followed.	
2	Remedial action o the observations by internal and external audits are taken appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being conducted which includes test system, the type of analysis , date on which analysis is done	
7	Review yearly 1- Report or input 2- Matter arising from previous reviews ; 3- Report of external audits, if any ; 4- Surveillance report, if any ; 5- Result of proficiency testing ; 6- Complaints or feedback received from users 7- Details of in-house quality control checks ; 8- Need of amendment of the quality system and documentation ; 9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	Standard Operation Procedures for the followings are required (i) Sample handling and accountability ; (ii) Receipt identification, storage, mixing and method sampling of the test and control articles ;	

S.N.	Details of the requirement	Remark
	(iii) Record keeping, reporting, storage and retrieval of data ; (iv) Coding of different studies, handling of data including use of computerized data system : (v) Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews ; (vi) Routing inspection of cleaning maintenance, testing, calibration and standardization of instruments ; (vii) Action to be taken in respect of equipment failure ; (viii) Analytical data methods (ix) Health and safety protection ; (x) Date handling and storage retrieval ; (xi) Health and safety protection ; (xii) Animal room preparations ; (xiii) Animal care ; (xiv) Storage and maintenance of microbial cultures ; (xv) Maintenance of sterility room (i.e. constant maintenance and monitoring of Aseptic condition room) ; (xvi) Use and storage of reference standards ; (xvii) Procurement of stores and equipment ; (xviii) Monitoring of testing of samples ; (xix) Method of retention of unexpended samples, their location, maintenance and disposal ; (xx) Document control ; (xxi) Redressal of technical complaints ; (xxii) House- keeping (xxiii) Corrective and preventive action ; (xxv) Calibration manual. (xxvi) Training manual.	
4	Protocols and specification archive :- List of all the pharmacopeias a file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. The test methods shall be submitted to the concerned Drug Control Authority.	
5	Raw data - Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.	
6	Storage and archival ; The residual sample shall be retained in proper storage condition for a period of one year after the final report.	
7	The laboratory must establish and maintain procedures for the identification collection, indexing, retrieval, storage, maintenance, and Disposal of all quality documents.	
8	All the raw date, documentation, SOP, protocols and final reports are the be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure their security and confidentiality.	

S.N.	Details of the requirement	Remark
10	Raw data on thermal paper might fad away with time ; therefore, a photocopy of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature:
Name of the Lab:
Date:
Official Seal:

ANNEXURE –IX
Ref: Clause no. 9 (2)

AGREEMENT

This Deed of Agreement is made on this _____day of_____ 2024 by M/s._____ represented by its Proprietor/ Managing partner /Managing Director having its laboratory Premises at _____ (hereinafter referred to as "Service provider" which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Whereas the Service provider has agreed to test the Drugs and Medicines for RMSC with specifications mentioned in the Schedule attached here to and mentioned at the prices noted there

in and in the manner and under the terms and conditions here in after mentioned and where as the Service provider has deposited with the Purchaser a sum of Rs_____(Rupees only) as Performance Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Service provider failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Service provider and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions including amendments contained in the invitation to tender floated for the Empanelment of Analytical Testing Laboratories for the test and Analysis of Drugs for Rajasthan Medical Services Corporation Ltd F.02(408)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2024/ Dated :- the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

1. (a) The Agreement is for the test by the Service provider to the Purchaser of the testing of Drug and Medicines specified in the Schedule attached here to at process noted against each therein on the terms and conditions set forth in the Agreement.

   (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no. …….and dated……and it shall remain in force up to 31.08.2026 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1. (a) In case the Service provider fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Service provider as Performance Security and cancel the Contract.

   (b) In case the Service provider fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Service provider under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Service provider as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the

Service provider having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Service provider to the Purchaser, either in his Tender or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Service provider. The Service provider will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

SERVICE PROVIDER NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Service provider shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Service provider give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Service provider permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SERVICE PROVIDER

5. In case the Service provider at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SERVICE PROVIDER

6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Service provider if delivered to him or left at his premises, place of business or abode.
7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SERVICER PROVIDER **(Signature, Name & Full Address)**	**Executive Director (Procurement),** **RAJASTHAN MEDICALSERVICES CORPORATION LTD.**

Witness (Signature, Name & Full Address)

1.

2.